三葉草生物-B(02197.HK)發售價定為每股13.38港元 預計11月5日掛牌上市
格隆匯11月4日丨三葉草生物-B(02197.HK)發佈公吿,公司全球發售1.5億股股份,其中香港發售股份1500萬股,國際發售股份1.35億股,另有15%超額配股權;發售價已釐定為每股發售股份13.38港元,每手買賣單位500股;高盛及中金公司為聯席保薦人;預期股份將於2021年11月5日於聯交所主板掛牌上市。
根據香港公開發售初步提呈發售的香港發售股份獲超額認購。公司合共接獲17,687份有效申請,認購合共6600.15萬股香港發售股份,相當於香港公開發售初步可供認購香港發售股份總數約4.40倍。國際發售初步提呈發售的發售股份已獲超額認購,相當於國際發售初步可供認購發售股份總數約3.21倍。按發售價每股13.38港元及根據基石投資協議,基石投資者認購合共8052.55萬股發售股份。
按發售價每股13.38港元計算,公司估計自全球發售收取所得款項淨額約18.702億港元(假設超額配股權並無獲行使)。公司擬將該等所得款項淨額約65%用於核心產品及相關產品的研發、生產及商業化;約22.5%將用於管線中其他產品的研發、生產及商業化;及約12.5%將用作營運資金及其他一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.